Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated ...

Le pipeline de Biogen a connu des avancées significatives au cours du T2 2025, avec des progrès dans plusieurs domaines thérapeutiques. La diapositive sur l’exécution de la stratégie met en évidence ...

Parmi les patients ayant reçu 40 doses ou plus sur 18 mois, 86,7% sont restés stables ou ont montré une amélioration clinique. La durée moyenne du traitement par lecanemab était de 375,4 jours, avec ...

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% ...

Biogen Inc. (NASDAQ:BIIB) is one of the top cheap pharmaceutical stocks to buy now. BofA lowered the firm’s price target on ...

Biogen beat Q2 estimates with cost control and new launches, but MS declines and pipeline risks cloud growth. Find out why ...

Biogen (NASDAQ:BIIB) stock rises as Q2 2025 results surpass expectations, driven by Alzheimer's drug Leqembi developed with ...

We came across a bullish thesis on Biogen Inc. on r/Valueinvesting subreddit by U/Lobyous. In this article, we will summarize ...

Biogen (BIIB) delivered earnings and revenue surprises of +39.19% and +13.89%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...

Investors in Biogen Inc (Symbol: BIIB) saw new options become available today, for the May 31st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BIIB options ...